Utilization of the ACQUITY PREMIER System and Column for Improved Oligonucleotide Bioanalytical Chromatographic Performance

Significance of the Topic

Oligonucleotide therapeutics are increasingly relied upon in drug discovery and clinical research. Accurate quantification in biological matrices is critical for pharmacokinetic and safety studies. Traditional LC-MS methods often suffer from analyte loss and poor reproducibility due to nonspecific adsorption of polyanionic oligonucleotides onto metal surfaces.

Study Objectives and Overview

This work evaluates the performance gains of the ACQUITY PREMIER System paired with its dedicated Oligonucleotide C18 Column. The focus is on two model analytes: a 20-mer and 35-mer oligodeoxythymidine (ODT) and the phosphorothioated antisense oligonucleotide therapy GEM91. Comparative assessments against a standard ACQUITY UPLC I-Class PLUS setup highlight improvements in recovery, peak shape, sensitivity, and reproducibility.

Methodology and Instrumentation

Sample preparation employed liquid–liquid extraction followed by SPE on a positive-pressure manifold. Chromatographic separation and detection details:

• Systems: ACQUITY PREMIER and ACQUITY UPLC I-Class PLUS
• Column: ACQUITY PREMIER Oligonucleotide C18 vs. standard Oligonucleotide C18
• Mass spectrometer: Xevo TQ-XS Tandem Quadrupole MS

MaxPeak High Performance Surfaces technology in the PREMIER system was engineered to reduce ionic interactions and metal adsorption without extended passivation steps or chelating additives.

Key Results and Discussion

The PREMIER setup delivered substantial improvements:

• Recovery increases up to 12-fold for GEM91 compared to the standard system
• Marked reduction in peak tailing, most pronounced for the 35-mer ODT
• Enhanced linearity: R2 improved from 0.996 to 0.999
• Lower limit of quantification for GEM91: 50 ng/mL in extracted plasma
• Precision (RSD) across calibration levels reduced to 0.95–7.2%
• Accuracy maintained within 90–119%

These gains were achieved without mobile phase passivation or signal-suppressing additives, translating to shorter system conditioning times and reduced reagent consumption.

Benefits and Practical Applications

The PREMIER technology streamlines method development by eliminating prolonged conditioning and chelator use. Laboratories benefit from improved throughput, lower operational costs, and robust quantification suitable for small-molecule bioanalytical validation criteria. Applications span preclinical screening, therapeutic monitoring, and quality control in oligonucleotide manufacturing.

Future Trends and Opportunities

Advances in surface chemistry will continue to mitigate nonspecific adsorption for a broader range of biopolymers. Integration with high-resolution MS and automated sample handling promises further throughput gains. Emerging oligonucleotide modalities, such as siRNA and mRNA therapeutics, represent potential application areas for enhanced LC-MS platforms.

Conclusion

Implementation of the ACQUITY PREMIER System and Oligonucleotide C18 Column provides a sensitive, precise, and reproducible platform for oligonucleotide bioanalysis. Significant gains in recovery, peak shape, and assay performance support its role in accelerating oligonucleotide drug development.

References

1. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. Pharm. Res. 2007;24:1962–1973.
2. Bansal S, DeStefano A. Key Elements of Bioanalytical Method Validation for Small Molecules. AAPS J. 2007;9:E109–114.